ReviewPharmaceutical research2010
Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.
Review in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- In vitro and in vivo metabolism of the synthetic cannabinoid FUB-144: comprehensive phase I and II profiling using UHPLC-HRMS.Archives of toxicology · 2026Article
- The Effect of Oxcarbazepine on the Pharmacokinetics of Single-Dose Aripiprazole in a Rat Model.Medicines (Basel, Switzerland) · 2026Article
- LLM-Enhanced Multimodal Framework for Drug-Drug Interaction Prediction.Biomedicines · 2025Article
- Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer.AAPS PharmSciTech · 2024Article
- Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022.Molecules (Basel, Switzerland) · 2023Review
- Molecular basis for selective uptake and elimination of organic anions in the kidney by OAT1.Nature structural & molecular biology · 2023Article
- In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III.International journal of molecular sciences · 2023Article
- Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.Frontiers in pharmacology · 2022Review
- Liver-Heart on chip models for drug safety.APL bioengineering · 2021Review
- Article
- Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.International journal of nanomedicine · 2017Article
- Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2017Article
- Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.The AAPS journal · 2016Review
- Engineering large animal models of human disease.The Journal of pathology · 2016Review
- Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs.European journal of drug metabolism and pharmacokinetics · 2014Article
- ADME of biologics-what have we learned from small molecules?The AAPS journal · 2012Review
- Molecular mass spectrometry imaging in biomedical and life science research.Histochemistry and cell biology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal models are used commonly in various stages of drug discovery and development to aid in the prospective assessment of drug-drug interaction (DDI) potential and the understanding of the underlying mechanism for DDI of a drug candidate. In vivo assessments in an appropriate animal model can be very valuable, when used in combination with in vitro systems, to help verify in vivo relevance of the in vitro animal-based results, and thus substantiate the extrapolation of in vitro human data to clinical outcomes. From a pharmacokinetic standpoint, a key consideration for rational selection of an animal model is based on broad similarities to humans in important physiological and biochemical parameters governing drug absorption, distribution, metabolism or excretion (ADME) processes in question for both the perpetrator and victim drugs. Equally critical are specific in vitro and/or in vivo experiments to demonstrate those similarities, usually both qualitative and quantitative, in the ADME properties/processes under investigation. In this review, theoretical basis and specific examples are presented to illustrate the utility of the animal models in assessing the potential and understanding the mechanisms of DDIs.
Indexed as
Identifiers
20428930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.